Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
76,302
Employees76,302
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
76,302
Employees76,302

NVO Key Statistics

Market cap
264.66B
Market cap264.66B
Price-Earnings ratio
17.29
Price-Earnings ratio17.29
Dividend yield
2.07%
Dividend yield2.07%
Average volume
23.04M
Average volume23.04M
High today
$60.39
High today$60.39
Low today
$58.41
Low today$58.41
Open price
$59.24
Open price$59.24
Volume
12.09M
Volume12.09M
52 Week high
$93.80
52 Week high$93.80
52 Week low
$43.08
52 Week low$43.08

NVO News

TipRanks 1d
Novo Nordisk Slides as Weight-Loss Drug War Escalates

Novo Nordisk ( (NVO) ) has fallen by -7.11%. Read on to learn why. Claim 50% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools for...

Nasdaq 1d
Should You Buy Novo Nordisk Stock on Oral Wegovy's Strong Launch?

Key Points In December, it earned approval for the oral version of its famous medicine. Novo Nordisk's newest product launch is proving very popular. It coul...

Should You Buy Novo Nordisk Stock on Oral Wegovy's Strong Launch?
Simply Wall St 1d
Novo Nordisk Oral Wegovy Launch Reshapes Obesity Access And Valuation Outlook

Novo Nordisk (NYSE:NVO) has launched an FDA approved oral version of its obesity drug Wegovy, expanding its GLP 1 obesity treatment portfolio. The company is w...

Novo Nordisk Oral Wegovy Launch Reshapes Obesity Access And Valuation Outlook

Analyst ratings

50%

of 34 ratings
Buy
50%
Hold
38.2%
Sell
11.8%

More NVO News

The Motley Fool 2d
Demand for Novo Nordisk's Weight Loss Pill Is Strong Out of the Gate. Is the Stock Due for a Big Rally?

Novo Nordisk's weight loss pill could give the company's numbers a big boost this year. Novo Nordisk (NVO +0.06%) got fantastic news last year when regulators...

Demand for Novo Nordisk's Weight Loss Pill Is Strong Out of the Gate. Is the Stock Due for a Big Rally?
CNBC 2d
Eli Lilly CEO says Medicare coverage of obesity drugs could 'change the game' for upcoming pill launch

Key Points Eli Lilly CEO Dave Ricks said upcoming Medicare coverage of obesity drugs could be a major catalyst for the launch of the company's closely watched e...

Eli Lilly CEO says Medicare coverage of obesity drugs could 'change the game' for upcoming pill launch
Benzinga 2d
Novo Nordisk Sued Over Alleged Scheme To Delay Generic Victoza In Favor Of Ozempic

Novo Nordisk A/S (NYSE:NVO) is accused of unlawfully extending its monopoly over its diabetes drug Victoza through a multiyear anticompetitive scheme designed t...

Novo Nordisk Sued Over Alleged Scheme To Delay Generic Victoza In Favor Of Ozempic
Sherwood News 3d
When is TrumpRx launching?

TrumpRx — the government’s drug pricing initiative, which is at the center of the tariff deals the administration has reached with drugmakers since September —...

When is TrumpRx launching?
Investor's Business Daily 3d
How Roche Hopes To Go Toe-To-Toe With Eli Lilly, Novo Nordisk In Obesity

Technology How Roche Hopes To Go Toe-To-Toe With Eli Lilly, Novo Nordisk In Obesity Licensing Roche (RHHBY) hopes to go toe-to-toe with Eli Lilly (LLY) and Novo...

How Roche Hopes To Go Toe-To-Toe With Eli Lilly, Novo Nordisk In Obesity
TipRanks 4d
Novo Nordisk Is Spending Twice as Much as Eli Lilly on Weight-Loss Drug Ads

European pharmaceutical company Novo Nordisk (NVO) is spending twice as much as its U.S. rival Eli Lilly on weight-loss drug advertisements. Data from advertis...

Simply Wall St 4d
Is Novo Nordisk Pricing Reflect Recent Share Weakness And DCF Upside Potential

If you are wondering whether Novo Nordisk's current share price still offers value, this article will walk through what the numbers say about the stock today....

Is Novo Nordisk Pricing Reflect Recent Share Weakness And DCF Upside Potential

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.